---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-064781"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:09:38.654323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 83% confirmed ORR in RAMP 205 dose level 1 for first-line metastatic pancreatic cancer

## Summary
- 83% (5/6) confirmed partial response in dose level 1 cohort; dose cleared after one DLT.
- 41 patients enrolled across 4 dose/schedule cohorts of avutometinib+defactinib+gemcitabine+nab-paclitaxel.
- 21 of 26 evaluable patients had reduction in target lesion sum of diameters as of May 14, 2024 cutoff.
- 12 patients experienced SAEs (11 grade ≥3); 2 discontinued due to treatment-emergent AEs.
- Investor call on May 24, 2024 to discuss these data and rolling NDA submission in recurrent KRAS mutant LGSOC.

## SEC filing metadata
- accession: 0001104659-24-064781
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465924064781/0001104659-24-064781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465924064781/tm2415352d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-064781
- JSON: https://secwatch.observer/filing/0001104659-24-064781.json
- Plain text: https://secwatch.observer/filing/0001104659-24-064781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.